Investor Relations
We invite all current and prospective shareholders, partners, and other interested
parties to browse our web site to learn more about the exciting developments at
our company. Investor inquires can be directed to
Gene Kelly or Trevor Heisler at 519-858-5157.
Why Invest in
Critical Outcome Technologies Inc.?
COTI is positioned to help build the pipeline and increase revenue for all sizes
of pharmaceutical companies
In recent years large pharmaceutical companies have been experiencing slowing sales
growth due to declining pipeline productivity and increasing patent expirations.
Drugs worth $15.3 billion will face generic competition in 2011 alone. By 2013,
13 US blockbuster drugs will lose patent protection. By 2016, drugs that generate
sales of $133 billion will face generic competition in the US. These current market
conditions will require pharmaceutical companies to shift their partnering approach.
COTI is positioned to decrease the cost and time associated with new drug development.
In 2008, 24 new drugs were approved by the FDA, the highest number since 2004, but
only 9 of these originated from Big Pharma. This low approval record is not a result
of dollars spent as America’s pharmaceutical research and biotechnology companies
invested a record $67.4 billion during 2010 on research and development -- an increase
of more than $1.5 billion from 2009.
According to the Pharmaceutical Research and Manufacturers of America (“PhRMA”)
only 1 of every 10,000 potential medicines investigated by America's research-based
pharmaceutical companies makes it through the research and development pipeline
and is approved by the FDA. Winning approval, on average, takes 15 years of R&D;
and costs more than $1 billion. The PhRMA 2010 Industry Proflie Report states that
only 2 of 10 marketed drugs ever produce revenues that match or exceed R&D; costs.
Partners who license a COTI product candidate can potentially reduce 2-4 years off
the current preclinical drug development timeline.
